Xiamen Amoytop Biotech Co., Ltd. Class A

As of June 30, 2026, Xiamen Amoytop Biotech Co., Ltd. Class A carries a market capitalization of 22.21B, placing it among publicly traded companies globally. Its enterprise value stands at 22.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Xiamen Amoytop Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Xiamen Amoytop Biotech Co., Ltd. Class A has 408.19M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Xiamen Amoytop Biotech Co., Ltd. Class A maintains a current ratio of 4.73, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Xiamen Amoytop Biotech Co., Ltd. Class A recorded 132.23M in income tax expense.

As of the close on October 22, 2026, Xiamen Amoytop Biotech Co., Ltd. Class A's stock has declined approximately 41.57% over the past 52 weeks. The 50-day moving average sits at 54.35, while the 200-day moving average is 62.46.

As of June 30, 2026, Xiamen Amoytop Biotech Co., Ltd. Class A holds 947.98M in cash and equivalents against 769.53M in total debt, resulting in a net debt position of -113.92M. Total book value stands at 3.10B, with working capital of 2.19B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Xiamen Amoytop Biotech Co., Ltd. Class A paid dividends of 0.62 per share.